Kala Pharmaceuticals, Inc. KALA announced that the FDA has accepted its investigational new drug (IND) application for its lead product candidate, KPI-012, which is being developed for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing.
More